September 18th, 2013
Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.
September 1st, 2013
Findings from the Hokusai-VTE trial of edoxaban
July 8th, 2013
This week’s topics include a home-based walking intervention for those with PAD, BNP screening and collaborative care for HF, clopidogrel with aspirin in acute minor stroke or transient ischemic attack, and more.
July 1st, 2013
In a large clinical trial the new oral anticoagulant apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) was at least as effective as standard therapy and caused fewer bleeding complications in patients with acute venous thromboembolism (VTE). The results of the AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) trial are being presented today at […]
March 26th, 2013
There’s been a remarkable increase in the use of IVC filters, but what is the evidence base behind this mechanistically appealing approach?
March 22nd, 2013
Use of the macrolide clarithromycin in patients admitted with exacerbations of chronic obstructive pulmonary disease or community-acquired pneumonia is associated with increased risk for cardiovascular events, a BMJ study finds. Researchers examined outcomes among nearly 3000 patients admitted to U.K. hospitals with either condition. During 1 year of follow-up, there were roughly 450 new admissions for […]
February 25th, 2013
This week’s topics include extended use of apixaban, dabigatran, warfarin, or placebo in VTE, the 5-year follow-up of the SYNTAX study, and more.
December 12th, 2012
John Ryan reviews the latest data and suggests that DVT/PE be managed as a chronic condition. Are you using apixaban in these patients, and how long are you treating them for?
December 8th, 2012
A new study suggests that extending anticoagulant therapy for an additional year may be beneficial after patients with venous thromboembolism complete their initial course of therapy. The results of AMPLIFY-EXT (Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment) were presented at the annual meeting of the American Society […]
October 29th, 2012
This week’s topics include CV risk factors and peripheral artery disease in men, radiofrequency ablation in paroxysmal AF, CPR duration and survival after in-hospital cardiac arrest, an everolimus-eluting stent vs. a bare-metal stent in STEMI, job strain and CHD, and more.